3 withdrawn. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Withdrawn 3 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Study of FCR001 in Adults With Rapidly Progressive Diffuse Cutaneous Systemic Sclerosis FCR001 - Diffuse Cutaneous Systemic Sclerosis | Phase 1 / Phase 2 | Withdrawn | Talaris Therapeutics Inc. | 2021-11-24 | 2023-10-12 | |
| Comparative Effectiveness Trial in the Treatment of Pediatric Plaque Morphea Clobetasol, Calcipotriene, Tacrolimus - Scleroderma | Phase 1 | Withdrawn | Medical College of Wisconsin | 2016-03-01 | 2018-07-18 | |
| Divalproex Sodium in the Treatment of the Cutaneous Manifestations of Scleroderma Divalproex sodium - Scleroderma, Systemic Sclerosis | Phase 1 / Phase 2 | Withdrawn | Yale University | 2014-06-01 | 2016-08-11 |
Connective Tissue Diseases (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Scleroderma, Systemic (2)
Clobetasol (1) · Tacrolimus (1) · Valproic Acid (1) · calcipotriene (1)
Medical College of Wisconsin (1) · Talaris Therapeutics Inc. (1) · Yale University (1)
United States (2)
Brett King, MD, PhD (1) · Joel Weinthal, MD (1) · Yvonne Chiu, MD (1)